| abstract |
The present invention addresses the treatment of age-related macular degeneration, and treatment of individuals with impaired visual function such as impaired dark adaptation, using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration and improving impaired dark adaptation. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide. |